Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 10th International Congress on Peritoneal Surface Malignancies
Transcript
10th International Congress on Peritoneal Surface Malignancies November 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC Course Director: Paul H. Sugarbaker, MD MedStar Surgical Oncology Washington, DC www.psogi2016.com Course Director Joel M. Baumgartner, MD, MAS, FACS Moores Cancer Center San Diego, CA, USA Paul H. Sugarbaker, MD, FACS, FRCS MedStar Washington Hospital Center Washington, DC, USA Lana Bijelic, MD Inova Fairfax Hospital Falls Church, VA, USA Scientific Organizing Committee Gina Brown, MD, FRCR The Royal Marsden London, UNITED KINGDOM David L. Bartlett, MD University of Pittsburgh Medical Center Pittsburgh, PA, USA Brendan J. Moran, MCh, FRCS, FRCSI The North Hampshire Hospitals Basingstoke, UNITED KINGDOM Marcello Deraco, MD Istituto Nazionale dei Tumori Milan, ITALY David Morris, MD St. George Hospital Kogarah, AUSTRALIA Olivier Glehen, MD, PhD Hospitalier Lyon Sud Lyon, FRANCE Pompiliu Piso, MD, PhD Hospital Barmherzige Brueder Regensburg, GERMANY Santiago Gonzalez-Moreno, MD, PhD MD Anderson Cancer Center Madrid Madrid, SPAIN Beate S. Rau, MD, PhD Charité Campus Mitte University Hospital Berlin, GERMANY Yan Li, MD, PhD Beijing Shijitan Hospital Beijing, CHINA Vic Verwaal, MD Aarhus University Hospital Aarhus, DENMARK John K. Chan, MD Palo Alto Medical Foundation Sutter Cancer Research Consortium California Pacific Medical Foundation San Francisco, CA, USA Yutaka Yonemura, MD, PhD Kishiwada Tokushukai Hospital Oosaka, JAPAN Dennis S. Chi, MD Memorial Sloan Kettering Cancer Center New York, NY, USA Faculty H. Richard Alexander Jr., MD University of Maryland Medical Center Baltimore, MD, USA Naoual Bakrin, MD, PhD Centre Hospitalier Lyon Sud Lyon, FRANCE Luca Ansaloni, MD Papa Giovanni XXIII Hospital Bergamo, ITALY Dario Baratti, MD Istituto Nazionale dei Tumori Milan, ITALY Peter H. Cashin, MD, PhD Uppsala University Uppsala, SWEDEN Tom Cecil, BM, DM Hampshire Hospitals Basingstoke, UNITED KINGDOM Wim Ceelen, MD, PhD Ghent University Hospital Ghent, BELGIUM Jean-Marc Classe, MD, PhD Institut de Cancérologie de l’Ouest Saint-Herblain Nantes, FRANCE Eelco de Bree, MD, PhD University Hospital Heraklion Heraklion, GREECE Ignace H. de Hingh, MD, PhD Catharina Cancer Institute Eindhoven, THE NETHERLANDS Clarisse Dromain, MD, PhD Institut Gustave Roussy Cancer Campus Grand Paris Paris, FRANCE Jesus Esquivel, MD Cancer Treatment Centers of America Philadelphia, PA, USA Anna Fagotti, MD, PhD Agostino Gemelli University Rome, ITALY Francois-Noel Gilly, MD, PhD Hospices Civils de Lyon Lyon, FRANCE Diane Goere, MD, PhD Institut Gustave Roussy Cancer Campus Grand Paris Paris, FRANCE Joji Kitayama, MD The University of Tokyo Tokyo, JAPAN Sebastian Rufián Peña, MD Hospital Universitario Reina Sofia Córdoba, SPAIN Shigeki Kusamura, MD, PhD Fondazione IRCCS Istituto Nazionale dei Tumori Milan, ITALY David P. Ryan, MD Massachusetts General Hospital Boston, MA, USA Laura A. Lambert, MD University of Massachusetts Medical School Worcester, MA, USA Edward A. Levine, MD Wake Forest Baptist Health Winston-Salem, NC, USA Haile Mahteme, MD Uppsala University Uppsala, SWEDEN Evgenia A. Halkia, MD Athens General Clinic Athens, GREECE Garrett M. Nash, MD, MPH Memorial Sloan Kettering Cancer Center New York, NY, USA Nader N. Hanna, MD University of Maryland St. Joseph Medical Center Baltimore, MD, USA Ahuja Nita, MD Johns Hopkins Hospital Baltimore, MD, USA Richard A. Hoefer Jr., DO Sentara Surgery Specialists Newport News, VA, USA Charles Honore, MD, PhD Institut Gustav Roussy Cancer Campus Grand Paris Paris, FRANCE James S. Jelinek, MD MedStar Washington Hospital Center Washington, DC, USA Sang-Yoon Park, MD, PhD National Cancer Center Goyang, REPUBLIC OF KOREA Marc Pocard, MD, PhD Lariboisière Hospital St. Louis Hospital Paris, FRANCE Francois Quenet, MD Institut Du Cancer De Montpellier Montpellier, FRANCE Steven A. Rosenberg, MD, PhD National Cancer Institute Bethesda, MD, USA Paolo Sammartino, MD, PhD Ospedale Policlinico Umberto Rome, ITALY Armando Sardi, MD, FACS The Institute for Cancer Care Mercy Medical Center Baltimore, MD, USA John D. Spiliotis, MD, PhD Metaxa Cancer Hospital Pireus, GREECE Pieter J. Tanis, MD, PhD University of Amsterdam Amsterdam, THE NETHERLANDS Antonios-Apostolos K. Tentes, MD, PhD Metropolitan Hospital Athens, GREECE Kiran K. Turaga, MD, MPH Medical College of Wisconsin Milwaukee, WI, USA Kurt Van der Speeten, MD, PhD Ziekenhuis Oost-Limburg Genk, BELGIUM Willemien Van Driel, MD, PhD Netherlands Cancer Institute- Antoni Van Leeuwenhoek Amsterdam, THE NETHERLANDS Frans A.N. Zoetmulder, MD, PhD Zomba Central Hospital Zomba, MALAWI Wednesday, November 16 Friday, November 18 Saturday, November 19 Evening Registration and Welcome Reception Registration and Meet the Professor Breakfast Breakouts Meet the Professor Breakfast Breakouts Thursday, November 17 SESSION V: Update on Clinical Trials in Gastric Cancer SESSION I: Update on Clinical Trials in Colorectal Cancer SESSION VI: Update on National/International Peritoneal Metastases Registries SESSION X: New Technologies to Optimize Management of Peritoneal Surface Malignancy • Keynote Lecture: Genomic Medicine as it Involves Peritoneal Metastases • Keynote Lecture: Bidirectional Adjuvant Normothermic Chemotherapy (BANC) Long-Term for Management of Ovarian Cancer • Keynote Lecture: 90% of the Adverse Outcomes Occur in 10% of Patients. Can We Identify the High Risk Groups? • Case Presentations: Prevention and Treatment of Peritoneal Metastases from Appendiceal Cancer SESSION II: Update on Clinical Trials in Ovarian Cancer SESSION III: Keynote Lecture, Debate & Best Abstracts Presentations • Keynote Lecture: Animal Models - What Can They Tell Us About the Management of Peritoneal Metastases? • Debate: Adjuvant HIPEC Is Superior/Inferior To SecondLook Surgery With HIPEC In High Risk Primary Colorectal Cancer For Peritoneal Metastases • Presentation of Best Abstracts (1-4) SESION IV: Debate & Case Presentations with Panel of Experts • Debate: CRS and HIPEC is/is not the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases in the United States • Case Presentations: Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer Evening Networking Welcome Reception Visit www.psogi2016.com for the most updated program information SESSION VII: Best Abstracts Presentations & Case Presentations • Presentation of Best Abstracts (5-8) • Case Presentations: Peritoneal Metastases from Gastric Cancer SESSION VIII: Keynote Lecture, Debate & Case Presentations • Keynote Lecture: Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases • Debate: Recurrent Ovarian Cancer – CRS Aand HIPEC is/ is not a Reasonable Treatment Option Now in Selected Patients • Case Presentations: CRS and HIPEC for Unusual Diseases SESSION IX: Keynote Lecture, Debate & Case Presentations • Keynote Lecture: Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain • Debate: Pharmacology and Clinical Data Show/Do Not Show, that Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer • Case Presentations: The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer Evening Congress Banquet with Historical Documentary: 30 Years of Progress in Treating Peritoneal Metastases Looking Ahead to the 2018 Congress in Paris POST- CONFERENCE SATELLITE PROGRAMS Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC Peritoneal Metastases Imaging Meet the Professor Breakfast Sessions On Friday, November 18 and Saturday, November 19, PSOGI 2016 will host 10 morning sessions that will include a continental breakfast. Each session will highlight a specific topic in a small group setting with international renowned leaders in the field. A complete listing of session titles and chairs can be found on www.psogi2016.com. Course Description Learning Objectives Registration Information In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. • Early Bird Registration Fees (NOW through April 29, 2016) The mission of the 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases. CME Accreditation MedStar Georgetown University Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation MedStar Georgetown University Medical Center designates this live activity for a maximum of 25.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Utilize available data to determine optimal treatment options including cytoreduction surgery plus HIPEC for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, appendiceal cancer, peritoneal mesothelioma) • List, classify and utilize quantitative prognostic indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC • Utilize the appropriate clinical pathways, patient protocols, and surgical procedures as recommended by a panel of international experts to optimize patient care • Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room • Improve patient selection, surgical technique and management and standardized HIPEC regiments which will result in improved patient outcomes • Identify patients at high risk for carcinomatosis or with low volume disease at the time of primary cancer Target Audience This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, gastroenterologists, gynecologists, pharmacologists, pathologists, and other healthcare professionals interested in peritoneal surface oncology. $500 — Physicians $350 — Advanced Practice Clinicians $350 — Allied Health Professionals $350 — Residents/Fellows $350 — Nurses April 30, 2016 through November 16, 2016* $700 — Physicians $550 — Advanced Practice Clinicians $550 — Allied Health Professionals $550 — Residents/Fellows $550 — Nurses Satellite Meeting: Scientific Research $150 — Physicians $100 — Residents/Fellows $100 — Advanced Practice Clinicians $100 — Allied Health Professionals *An additional $100 will be added to Onsite Registrations November 17-19 Venue Information Omni Shoreham Hotel 2500 Calvert Street, NW Washington, DC 20007 Room Block Rate: $239 night plus applicable tax Please call Omni Reservations at 1-800-THE-OMNI (1-800-843-6664) or 202-234-0700 to book your room today! Reservations can also be made online by visiting www.psogi2016.com. When making reservations by phone, please indicate that you are a part of the “10th International Congress on Peritoneal Surface Malignancies Group”
